Valuation: Cardiol Therapeutics Inc.

Market Cap 19Cr 13Cr 12Cr 11Cr 9.94Cr 1.25TCr 19Cr 131.2Cr 51Cr 650.62Cr 49Cr 48Cr 2.08TCr P/E 2026 *
-3.33x
P/E 2027 * -5.45x
Enterprise Value 17Cr 12Cr 11Cr 9.81Cr 8.92Cr 1.12TCr 17Cr 117.83Cr 46Cr 584.31Cr 44Cr 43Cr 1.87TCr EV / Sales 2026 *
-
EV / Sales 2027 * 108x
Free-Float
97.73%
Yield 2026 *
-
Yield 2027 * -
23/09 Cardiol Therapeutics Achieves Phase III Maveric Enrollment Target Ahead of Schedule and Expands Pivotal Trial CI
23/09 Cardiol Therapeutics Inc. Achieves MAVERIC Enrollment Target And Expands Pivotal Trial Evaluating CardiolRx CI
13/08 Cardiol Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
12/05 Cardiol Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
07/05 Cardiol Adds Results "Further Validate" Ongoing Phase III Trial, Which Recently Surpassed 75% Enrollment MT
07/05 Cardiol Says Results Demonstrate CardiolRx "May Represent a Paradigm Shift" In the Treatment of Patients With Recurrent Pericarditis MT
07/05 Cardiol Therapeutics Says Its Phase II MAvERIC Results Accepted For Publication In The Journal Of The American Heart Association MT
07/05 Cardiol Therapeutics Inc Announces Phase II Maveric Results Accepted for Publication in the Journal of the American Heart Association CI
28/04 Cardiol Therapeutics Up In US Premarket As Expands Phase 3 Maveric Trial to Include 7 More Clinical Centers in the U.S. MT
28/04 Cardiol Therapeutics Inc. Expands Maveric Phase III Trial Network and Provides Clinical Updates on Cardiolrx CI
01/04 Cardiol Therapeutics Fiscal 2025 Loss Narrows; Says Now Fully Funded Through Completion of MAVERIC trial MT
01/04 Cardiol Therapeutics initiated pivotal Phase III Maveric trial of Cardiolrx in recurrent pericarditis RE
01/04 Cardiol Therapeutics Inc. Provides Update on Strategic Priorities CI
1 week-13.51%
Current month-32.49%
1 month-37.98%
3 months+1.27%
6 months-17.95%
Current year+22.14%
1 week 1.6
Extreme 1.6
1.76
1 month 1.6
Extreme 1.6
2.78
Current year 1.22
Extreme 1.225
3.23
1 year 1.22
Extreme 1.225
3.23
3 years 0.91
Extreme 0.91
4.26
5 years 0.61
Extreme 0.61
6.11
10 years 0.61
Extreme 0.61
8.49
Manager TitleAgeSince
Chief Executive Officer - 19/01/2017
Director of Finance/CFO - 16/08/2018
Chief Operating Officer - 03/12/2020
Director TitleAgeSince
Director/Board Member - 15/12/2017
Director/Board Member - 19/01/2017
Chairman - 07/07/2021
Date Insider Type Main position Quantity % Market Cap. Importance
08/09/26 Option

Chairman

25,000 0.0214%
08/09/26 Option

Chairman

-25,000 0.0214%
28/08/26 Option

Chief Technology Officer

-70,000 0.0599%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-13.51%+4.58%+45.45% 13Cr
+0.21%-4.63%+55.34%+71.32% 6.89TCr
+1.66%+7.51%+8.12%+60.04% 5.19TCr
+3.14%+7.17%+12.48%+44.42% 4.87TCr
+3.45%+4.70%+33.44%+35.96% 4.31TCr
-2.20%+0.61%+281.88%+532.76% 4.15TCr
+6.43%+6.84%+18.32%+109.23% 4TCr
+1.28%+1.39%+11.69%+45.10% 3.06TCr
+2.47%-7.45%+35.95%+1.71% 2.6TCr
+1.74%-2.02%-13.55%-12.92% 2.23TCr
Average +1.82%-2.20%+44.82%+93.31% 3.73TCr
Weighted average by Cap. +1.90%-0.26%+52.80%+105.47%

Financials

2026 *2027 *
Net sales - 16.67L 11.74L 10.48L 10L 9L 11Cr 16.97L 1.17Cr 45.77L 5.8Cr 44.05L 43.12L 19Cr
Net income -3.61Cr -2.54Cr -2.27Cr -2.11Cr -1.92Cr -240.87Cr -3.68Cr -25Cr -9.92Cr -125.68Cr -9.54Cr -9.34Cr -402.15Cr -3.79Cr -2.67Cr -2.39Cr -2.22Cr -2.02Cr -253.13Cr -3.86Cr -27Cr -10Cr -132.07Cr -10Cr -9.82Cr -422.61Cr
Net Debt -1.91Cr -1.34Cr -1.2Cr -1.11Cr -1.01Cr -127.1Cr -1.94Cr -13Cr -5.23Cr -66Cr -5.04Cr -4.93Cr -212.2Cr -65.94L -46.45L -41.46L -38.53L -35.05L -44Cr -67.13L -4.63Cr -1.81Cr -23Cr -1.74Cr -1.71Cr -73Cr
Projected Income Statement - Annual - Cardiol Therapeutics Inc.
Logo Cardiol Therapeutics Inc.
Cardiol Therapeutics Inc. is a Canada-based clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. The Company's lead small-molecule drug candidate, CardiolRx (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease. It holds investigational new drug application authorization from the United States Food and Drug Administration (US FDA) to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart: recurrent pericarditis and acute myocarditis. The MAVERIC Program in recurrent pericarditis, an inflammatory disease, comprises the completed Phase II MAvERIC-Pilot study (NCT05494788) and the ongoing Phase III MAVERIC trial (NCT06708299). The Company is also developing CRD-38, a novel subcutaneously administered drug formulation intended for use in heart failure.
Employees
18
Date Price Change Volume
15/26/15 CA$1.600 0.00% 2,79,428
14/26/14 CA$1.600 -6.43% 1,58,351
13/26/13 CA$1.710 -3.93% 2,17,553
09/26/09 CA$1.780 -3.78% 1,79,622
08/26/08 CA$1.850 0.00% 2,10,885
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Cardiol Therapeutics Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
1.600CAD
Average target price
7.000CAD
Spread / Average Target
+337.50%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Cardiol Therapeutics Inc.
  1. Stock Market
  2. Stocks
  3. CRDL Stock